NASDAQ:ADAPAdaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADAP stock has increased by 276.5% and is now trading at $11.07. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adaptimmune Therapeutics.

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Adaptimmune Therapeutics.

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) released its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The biotechnology company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $25.90 million. Adaptimmune Therapeutics had a negative net margin of 7,324.48% and a negative return on equity of 85.62%. View Adaptimmune Therapeutics' earnings history.

6 analysts have issued twelve-month price targets for Adaptimmune Therapeutics' stock. Their forecasts range from $3.00 to $7.00. On average, they anticipate Adaptimmune Therapeutics' stock price to reach $5.00 in the next year. This suggests that the stock has a possible downside of 54.8%. View analysts' price targets for Adaptimmune Therapeutics.

News headlines about ADAP stock have been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of -3.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAdaptimmune Therapeutics.

Adaptimmune Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 812,400 shares, an increase of 14.6% from the April 15th total of 708,600 shares. Based on an average daily trading volume, of 517,400 shares, the short-interest ratio is currently 1.6 days. Currently, 0.9% of the company's shares are short sold. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Fate Therapeutics (FATE), Alector (ALEC), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Cortexyme (CRTX) and Translate Bio (TBIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Micron Technology (MU) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Matrix Capital Management Company LP (26.47%), NEA Management Company LLC (13.13%), RA Capital Management L.P. (9.64%), Capital World Investors (6.15%), Baillie Gifford & Co. (3.35%) and Orbimed Advisors LLC (1.94%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, Elliot Norry, Enterprise Associates 14 New, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Orbimed Advisors Llc, Peter A Thompson, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr. View institutional ownership trends for Adaptimmune Therapeutics.

ADAP stock was sold by a variety of institutional investors in the last quarter, including Rathbone Brothers plc, Polygon Management Ltd., GSA Capital Partners LLP, Raymond James & Associates, and WS Management Lllp. Company insiders that have sold Adaptimmune Therapeutics company stock in the last year include Adrian Rawcliffe, Elliot Norry, James Noble, John Lunger, Rafael Amado, and William C Bertrand, Jr. View insider buying and selling activity for Adaptimmune Therapeutics.

ADAP stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Matrix Capital Management Company LP, NEA Management Company LLC, Capital World Investors, Orbimed Advisors LLC, Capital International Investors, Rock Springs Capital Management LP, and Baillie Gifford & Co.. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, Enterprise Associates 14 New, Lawrence M Alleva, and Peter W Sonsini. View insider buying and selling activity for Adaptimmune Therapeutics.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $11.07.

Adaptimmune Therapeutics has a market capitalization of $1.44 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.

The official website for Adaptimmune Therapeutics is www.adaptimmune.com.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]